secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001104659-24-031458
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharmaceuticals terminates CVRs from prior spin-off; no financial impact
------------------------------------------------------------------------------

- CVRs originated from 2021 sale of Cellect Biotherapeutics to EnCellX; Quoin not entitled to proceeds.
- Termination certified by EnCellX CEO on Feb 29, 2024; CVRs had no asset or liability recorded.
- CVR termination has no financial impact on Quoin; no carrying value on balance sheet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924031458/0001104659-24-031458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924031458/tm248148d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-031458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer